Ambrx

Ambrx’s ARX517 Impresses in Prostate Cancer Trial (ESMO 2023)

Ambrx’s ARX517 Shows Promising Efficacy and Safety in Advanced Prostate Cancer (ESMO 2023)

Anika Sharma

ESMO 2023: 1804P As of the data cutoff date in September 2023, the results from the study show that increasing ...